More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...

In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the ...

Dr Peter Bloomfield, director of research at the Macular Society, reflects on research developments and the meaningful ...

New research highlights progress in treating age-related macular degeneration, including late‑stage drug trials, gene therapy strategies, and a wireless retinal prosthesis that restored limited ...

WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49 th Macula Society ...

Dry age-related macular degeneration (AMD) management is currently based on regular follow-up for early detection of choroidal neovascularization (CNV), addressing the risk factors and prescribing ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

The 2003 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) was held in May in Fort Lauderdale, Florida. The retinal sessions were dominated by reports of new treatments ...

A laser treatment for this common eye disease will start clinical trials in Finland next spring ––researchers hope it could be available to sufferers in as little as three years Around a third of ...